Share

April 13, 2021; 96 (15 Supplement) Saturday, April 17

Short term relapse risk after switching from natalizumab to ocrelizumab or cladribine – an international cohort study (1712)

Johanna Treffts, Yan Van Kesteren, Sandra Thiel, Alexander Stahmann, Melinda Magyari, Achim Berthele, Katrin Giglhuber, Stefan Bittner, Erik Ellwardt, Klemens Angstwurm, Björn Tackenberg, Jan Jurs, Andrea Viehover, Luisa Klotz, Lena Theis, Ralf Gold, David Ellenberger, Kerstin Hellwig
First published April 13, 2021,
Citation
Permissions

Make Comment

See Comments

Downloads
0

Share

Article Information

vol. 96 no. 15 Supplement 1712
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Print ISSN: 
0028-3878
Online ISSN: 
1526-632X
History: 
  • First Published April 13, 2021.
Copyright & Usage: 
© 2021

Author Disclosures

    1. Johanna Treffts1,
    2. Yan Van Kesteren1,
    3. Sandra Thiel1,
    4. Alexander Stahmann2,
    5. Melinda Magyari3,
    6. Achim Berthele4,
    7. Katrin Giglhuber4,
    8. Stefan Bittner5,
    9. Erik Ellwardt5,
    10. Klemens Angstwurm6,
    11. Björn Tackenberg7,
    12. Jan Jurs7,
    13. Andrea Viehover8,
    14. Luisa Klotz9,
    15. Lena Theis1,
    16. Ralf Gold1,
    17. David Ellenberger2 and
    18. Kerstin Hellwig1
  1. Johanna Treffts1,
  2. Yan Van Kesteren1,
  3. Sandra Thiel1,
  4. Alexander Stahmann2,
  5. Melinda Magyari3,
  6. Achim Berthele4,
  7. Katrin Giglhuber4,
  8. Stefan Bittner5,
  9. Erik Ellwardt5,
  10. Klemens Angstwurm6,
  11. Björn Tackenberg7,
  12. Jan Jurs7,
  13. Andrea Viehover8,
  14. Luisa Klotz9,
  15. Lena Theis1,
  16. Ralf Gold1,
  17. David Ellenberger2 and
  18. Kerstin Hellwig1
  1. 1Department of Neurology, St. Josef Hospital, Ruhr University, Bochum, Germany
  2. 2DMSG - Die Gruppe
  3. 3Danish MS Reseach Center, Rigshospitalet
  4. 4Technische Universität München
  5. 5Klinik und Poliklinik für Neurologie der Universitätsmedizin Mainz
  6. 6Universität Regensburg
  7. 7Universitätsklinikum Marburg
  8. 8Universität Heidelberg
  9. 9Uniklinik Münster

Article usage

Article usage: April 2021 to November 2023

AbstractFullPdfSource
Apr 20211100Highwire
May 20212400Highwire
Jun 20212000Highwire
Jul 20211700Highwire
Aug 2021700Highwire
Sep 20211700Highwire
Oct 20211800Highwire
Nov 20212000Highwire
Dec 2021600Highwire
Jan 2022900Highwire
Feb 20221900Highwire
Mar 20222100Highwire
Apr 2022700Highwire
May 20222600Highwire
Jun 20221000Highwire
Jul 2022900Highwire
Aug 2022800Highwire
Sep 20221200Highwire
Oct 20222700Highwire
Nov 20222600Highwire
Dec 2022800Highwire
Jan 20232000Highwire
Feb 20231000Highwire
Mar 20231400Highwire
Apr 2023600Highwire
May 2023800Highwire
Jun 20231600Highwire
Jul 2023600Highwire
Aug 2023300Highwire
Sep 2023600Highwire
Oct 2023800Highwire
Nov 2023900Highwire

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. [email protected]
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

  • No related articles found.

Alert Me